<DOC>
	<DOC>NCT02612558</DOC>
	<brief_summary>The purpose of this study is to evaluate whether fostamatinib is safe and effective in treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).</brief_summary>
	<brief_title>A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Anemia, Hemolytic</mesh_term>
	<mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<criteria>Subject must have had a diagnosis of primary or secondary warm antibody AIHA. Must have failed at least 1 prior treatment regimen for AIHA. Subject with cold antibody AIHA, cold agglutinin syndrome, mixed type AIHA, or paroxysmal cold hemoglobinuria. Subject with a platelet count of &lt; 30,000/μL. Subject has AIHA secondary to autoimmune disease, including systemic lupus erythematosis (SLE), or lymphoid malignancy and the underlying disease is not stable or is not wellcontrolled on current therapy. Subject has uncontrolled or poorly controlled hypertension, defined as systolic blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥ 90 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Warm antibody autoimmune hemolytic anemia (AIHA)</keyword>
</DOC>